• Celcuity's lead drug candidate, gedatolisib, produced positive Phase 3 results in the VIKTORIA-1 trial for PIK3CA-mutant HR+/HER2- metastatic breast cancer.
• The trial met its primary endpoint and showed a significant improvement in progression-free survival.
• Celcuity plans to submit a supplemental NDA to the FDA, with full data scheduled for presentation at ASCO 2026.
• The program follows an existing Priority Review for gedatolisib in the wild-type population, with an FDA decision pending.

For investors tracking smaller oncology developers, Celcuity (NasdaqCM:CELC) now has a material late-stage data point for its lead asset. The stock last closed at $130.71, with very large 1-year and 3-year returns and a 30.0% gain year to date. This puts the current news in the context of an already strong share price move.

Positive Phase 3 results and upcoming regulatory milestones can be key catalysts, as they often influence how investors weigh clinical risk against commercialization potential. As the supplemental NDA filing progresses and ASCO 2026 approaches, your focus may shift to regulatory timing, label scope, and how gedatolisib might fit within existing breast cancer treatment options.

Stay updated on the most important news stories for Celcuity by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Celcuity.

This update gives Celcuity a clearer path toward turning gedatolisib from a clinical asset into a commercial product. The VIKTORIA-1 mutant cohort not only hit its primary endpoint, it showed progression-free survival benefits over alpelisib, a currently approved PI3K inhibitor, in both triplet and doublet regimens. For investors, that points to a product story that targets a specific genetic subgroup while also sitting alongside the already filed Priority Review in the wild-type setting with a PDUFA date of 17 July 2026. If both indications advance, Celcuity could be addressing a meaningful portion of the HR+/HER2- metastatic breast cancer market where resistance to current therapies is a recurring issue. At the same time, the company remains pre revenue and is investing heavily ahead of potential launches, so the timeline from positive data to sustainable cash flows is still a key question. Competitively, any future label will need to stand up against options from larger oncology players such as Novartis, Pfizer and Eli Lilly, where combinations and sequencing choices are already well established.

How This Fits Into The Celcuity Narrative

• This VIKTORIA-1 readout supports the existing narrative that potential FDA approvals in second line HR+/HER2- breast cancer could start to convert gedatolisib data into product revenue across multiple lines of therapy.
• The need for further trials such as VIKTORIA-2 and possible additional endocrine-sensitive studies highlights that the pathway to broad adoption across all targeted indications may be more staggered than a single trial outcome implies.
• The specific outperformance versus alpelisib and the focus on PIK3CA-mutant disease are not fully reflected in the higher level narrative, which mainly discusses the overall addressable market rather than how head-to-head data might influence share within that market.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Celcuity to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Celcuity currently makes less than US$1m in revenue, so the business is still reliant on external funding while it prepares for possible commercialization.
• ⚠️ Shareholders have been diluted in the past year, and further capital needs could lead to additional dilution if revenue does not ramp as planned.
• 🎁 The stock is trading below analyst price targets, and analysts as a group expect meaningful earnings growth if the pipeline progresses as planned.
• 🎁 Simply Wall St currently assesses Celcuity as trading well below its estimate of fair value, which some investors may see as an opportunity if the clinical and regulatory milestones are achieved.

What To Watch Going Forward

From here, the key checkpoints are the supplemental NDA submission for the PIK3CA-mutant population, the Priority Review decision in the wild-type setting on 17 July 2026, and the detailed VIKTORIA-1 data presentation at ASCO 2026. Investors may also want to watch updates on VIKTORIA-2 and other gedatolisib trials, since extending use into earlier lines of therapy or additional tumor types could influence the long term revenue mix. On the financial side, quarterly reports on cash use, any new financing and commercial build out plans will help frame how long Celcuity can fund this transition period without heavier dilution or higher debt.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Celcuity, head to the community page for Celcuity to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.